Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07459283
EARLY_PHASE1

The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors

Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. The dosing schedule and dose could also be adjusted according to the patient's condition. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.

Official title: Evaluation of the Safety, Dosimetry and Efficacy of 177Lu-INN805 Injection in Patients With Malignant Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-04

Completion Date

2027-03

Last Updated

2026-03-10

Healthy Volunteers

No

Interventions

DRUG

INN805

The drug was administered once every 6 weeks. It was expected that the drug would be administered for 1 to 4 cycles.

Locations (1)

Affiliated Hospital of Jiangnan University

Wuxi, Jiangsu, China